A blonde analyst compares four healthcare stocks on AI Stock Platform charts.

Editorial team research

Four biotech stocks, two business models: IONS and AXSM lead while TWST edges TXG

Axsome has the clearest product-sales growth, Ionis the broadest recent clinical progress, and Twist the stronger operating trend among two life-science tools companies. The four should not be judged as one trade.

Data as of 2026-09-25

IONSAXSMTWSTTXG

Four biotech stocks, two business models: IONS and AXSM lead while TWST edges TXG

Key takeaways

  • Axsome Therapeutics has the strongest demonstrated product growth: second-quarter 2026 net product revenue climbed 46% to $218.4 million. The cost of expanding its commercial reach remains the test.
  • Ionis Pharmaceuticals has the broadest collection of recent clinical and regulatory successes, plus a substantial cash reserve. New launches must turn that progress into repeatable product revenue.
  • In research tools, Twist Bioscience has the better current growth evidence. 10x Genomics has financial flexibility, but its underlying sales growth is still modest.

These four names are often grouped under “biotech,” yet they sell different things. AXSM and IONS develop medicines and face launch, clinical and regulatory risk. TWST and TXG supply research tools, where customer spending, instrument adoption and recurring consumable demand matter more. As of September 25, 2026, the strongest business cases are AXSM and IONS; TWST is the more convincing of the tools pair. That is not a ranking of today's entry prices. The supplied intraday price context was checked around 09:44 a.m. ET and can change quickly, while the operating evidence below comes from company releases and filings.

AXSM: product growth is already visible

AXSM reported $218.4 million of second-quarter net product revenue, up 46% year over year. Auvelity contributed $180.3 million, up 51%, and its new U.S. indication for agitation associated with Alzheimer's dementia launched in June. The question is no longer whether the company can sell a product; it is whether the expanded sales effort produces enough incremental demand to justify its cost. Selling, general and administrative expense rose to $208.1 million from $130.3 million a year earlier, and AXSM posted a $51.3 million quarterly net loss. Its next reports need to show Auvelity's broader use translating into durable sales growth and better operating leverage. AXSM's Q2 results provide the sales and expense figures.

IONS: more validated programs, but launch execution matters

Ionis ended June with $2.1 billion of cash and short-term investments. Since then, U.S. regulators approved ZANVASTRO (zilganersen) for Alexander disease. Partnered Phase 3 programs also produced positive FUS-ALS topline results and positive interim IgA-nephropathy data. These are distinct programs at different commercial stages; trial success is not the same as approval or immediate Ionis product sales.

The revenue mix is the caution. Ionis reported $268 million of second-quarter total revenue, but $149 million came from research and development arrangements, including collaboration and joint-development revenue. Investors should watch TRYNGOLZA and DAWNZERA sales, the ZANVASTRO launch and regulatory follow-through on partnered programs—not treat the whole $268 million as recurring medicine sales. Ionis's Q2 report separates those categories.

TWST versus TXG: the tools gap is growth, not science

Twist's fiscal third-quarter revenue rose 23% to $118.4 million, with growth across DNA synthesis and next-generation-sequencing applications. That makes its current operating trajectory stronger than TXG's, but it does not make TWST profitable: the quarter brought a $35.1 million GAAP net loss. Management reiterated a goal of adjusted EBITDA breakeven in fiscal Q4, a non-GAAP milestone that must not be confused with GAAP profitability. Twist also priced a $300 million equity offering in August, increasing its share count. The next tests are Q4 revenue delivery, margins and dilution-adjusted progress. Twist's Q3 filing details the operating results.

TXG remains a significant single-cell and spatial-biology tools company, with $552 million in cash, equivalents and marketable securities at June 30. Yet its second-quarter revenue grew only 3% year over year after excluding one-time patent-settlement revenue in both periods. Management highlighted early customer interest in new products; the investment case needs that interest to become sustained orders and faster underlying revenue growth. Its cash balance provides time, not proof of acceleration. 10x Genomics' Q2 filing sets out the adjusted comparison.

Bottom line

AXSM offers the clearest commercial proof, but must earn back rising selling costs. IONS offers the deepest near-term pipeline and regulatory record, but its own product launches have more to prove than its headline revenue suggests. TWST leads the two tools businesses on growth, tempered by losses and dilution. TXG has resources and technology, but needs a more decisive improvement in underlying demand. For an investor, those are four different checkpoints—not a single “biotech rally” signal.

Methodology: This is a business and catalyst comparison dated September 25, 2026, using the supplied market-price context checked around 09:44 a.m. ET; no point-in-time share prices are used to set entry levels. Financial figures are from the linked company releases and SEC filings. Clinical and management targets are not guaranteed outcomes. Research only, not investment advice.

Sources